Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dip Jadav

Ophthalmology Sugar Land, TX Medical Doctor

NPI 1497908883 CMS profile 633687

3507 Town Center Blvd S, Sugar Land, TX 77479

Open in the dashboard

General payments

$3,700

191 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dip Jadav of Sugar Land, TX is reported in the CMS Open Payments database as having received $3,700 across 191 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $547 29
2024 General $450 21
2023 General $594 31
2022 General $370 17
2021 General $196 12
2020 General $205 25
2019 General $1,338 56

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dip Jadav
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Dip Jadav were reported at $547. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Dip Jadav Ophthalmology median Middle half National median
2019 $1,338 $258 $104–$655 $163
2020 $205 $126 $45–$321 $114
2021 $196 $205 $76–$534 $132
2022 $370 $266 $100–$678 $149
2023 $594 $308 $117–$745 $160
2024 $450 $340 $127–$846 $164
2025 $547 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alcon Vision LLC $1,201 29 payments
  2. Sun Pharmaceutical Industries Inc. $638 73 payments
  3. AbbVie, Inc. $423 22 payments
  4. Ocular Therapeutix, Inc. $255 12 payments
  5. TissueTech, Inc. $169 8 payments
  6. Glaukos Corporation $161 6 payments
  7. Kala Pharmaceuticals, Inc. $75 4 payments
  8. Bausch & Lomb, a division of Bausch Health US, LLC $74 4 payments
  9. Tarsus Pharmaceuticals, Inc. $69 2 payments
  10. Carl Zeiss Meditec, Inc. $68 1 payment
  11. Other $567 30 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,967 186 payments
  2. Travel and Lodging $592 3 payments
  3. Long term medical supply or device loan $140 2 payments
Products named General payments · program years 2019–2025
  1. Cequa $432 42 payments
  2. BromSite $340 49 payments
  3. AcrySof $282 5 payments
  4. LUMIGAN $271 16 payments
  5. ALPHAGAN P $174 11 payments
  6. VUITY Ophthalmology $168 7 payments
  7. VUITY Eye Care $118 7 payments
  8. DEXTENZA $115 10 payments
  9. LOTEMAX SM $93 5 payments
  10. PROLENSA $93 5 payments
  11. Other $1,755 93 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

3,578

Median for Ophthalmology: 891

Drug cost

$340,115

Median for Ophthalmology: $68,233

Branded share of claims

34.4%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lumigan Bimatoprost Brand 138 $79,301
Restasis Cyclosporine Brand 39 $51,464
Azelastine Hcl Generic 596 $28,459
Miebo Perfluorohexyloctane/Pf Brand 29 $23,219
Xiidra Lifitegrast Brand 18 $21,999
Cyclosporine Generic 36 $19,660
Prednisolone Acetate Generic 350 $16,239
Rocklatan Netarsudil Mesylat/Latanoprost Brand 25 $15,150
Vyzulta Latanoprostene Bunod Brand 20 $12,414
Moxifloxacin Moxifloxacin Hcl Brand 217 $9,025

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$426,292

Medicare's payments for the services billed

Medicare patients

833

Average age 74

Services billed

3,916

481 women, 352 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 56%
Arthritis 53%
Ischemic heart disease 34%
Chronic kidney disease 33%
Osteoporosis 23%
Heart failure 15%
Depression 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LUMIGAN
  • AbbVie, Inc. $69
$69 138 —
XDEMVY
  • Tarsus Pharmaceuticals, Inc. $34
$34 — —
Rocklatan
  • Alcon Vision LLC $25
$25 25 —
IYUZEH
  • Thea Pharma Inc. $18
$18 — —
VEVYE
  • Harrow Eye, LLC $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

191 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record